These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 31455821)

  • 1. PIDD interaction with KEAP1 as a new mutation-independent mechanism to promote NRF2 stabilization and chemoresistance in NSCLC.
    Ji L; Zhang R; Chen J; Xue Q; Moghal N; Tsao MS
    Sci Rep; 2019 Aug; 9(1):12437. PubMed ID: 31455821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers.
    Yamadori T; Ishii Y; Homma S; Morishima Y; Kurishima K; Itoh K; Yamamoto M; Minami Y; Noguchi M; Hizawa N
    Oncogene; 2012 Nov; 31(45):4768-77. PubMed ID: 22249257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of KEAP1/NFE2L2 Mutations in the Chemotherapeutic Response of Patients with Non-Small Cell Lung Cancer.
    Jeong Y; Hellyer JA; Stehr H; Hoang NT; Niu X; Das M; Padda SK; Ramchandran K; Neal JW; Wakelee H; Diehn M
    Clin Cancer Res; 2020 Jan; 26(1):274-281. PubMed ID: 31548347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Keap1-Nrf2 Interaction Suppresses Cell Motility in Lung Adenocarcinomas by Targeting the S100P Protein.
    Chien MH; Lee WJ; Hsieh FK; Li CF; Cheng TY; Wang MY; Chen JS; Chow JM; Jan YH; Hsiao M; Hua KT; Kuo ML
    Clin Cancer Res; 2015 Oct; 21(20):4719-32. PubMed ID: 26078391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer.
    Singh A; Misra V; Thimmulappa RK; Lee H; Ames S; Hoque MO; Herman JG; Baylin SB; Sidransky D; Gabrielson E; Brock MV; Biswal S
    PLoS Med; 2006 Oct; 3(10):e420. PubMed ID: 17020408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulatory role of KEAP1 and NRF2 in PPARγ expression and chemoresistance in human non-small-cell lung carcinoma cells.
    Zhan L; Zhang H; Zhang Q; Woods CG; Chen Y; Xue P; Dong J; Tokar EJ; Xu Y; Hou Y; Fu J; Yarborough K; Wang A; Qu W; Waalkes MP; Andersen ME; Pi J
    Free Radic Biol Med; 2012 Aug; 53(4):758-68. PubMed ID: 22684020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baicalin promotes the sensitivity of NSCLC to cisplatin by regulating ferritinophagy and macrophage immunity through the KEAP1-NRF2/HO-1 pathway.
    Chen Y; Bao S; Wang Z; Fang Z; Tang H
    Eur J Med Res; 2024 Jul; 29(1):387. PubMed ID: 39061086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of KEAP1/NFE2L2/CUL3 mutations on duration of response to EGFR tyrosine kinase inhibitors in EGFR mutated non-small cell lung cancer.
    Hellyer JA; Stehr H; Das M; Padda SK; Ramchandran K; Neal JW; Diehn M; Wakelee HA
    Lung Cancer; 2019 Aug; 134():42-45. PubMed ID: 31319993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and Pathological Characteristics of
    Frank R; Scheffler M; Merkelbach-Bruse S; Ihle MA; Kron A; Rauer M; Ueckeroth F; König K; Michels S; Fischer R; Eisert A; Fassunke J; Heydt C; Serke M; Ko YD; Gerigk U; Geist T; Kaminsky B; Heukamp LC; Clement-Ziza M; Büttner R; Wolf J
    Clin Cancer Res; 2018 Jul; 24(13):3087-3096. PubMed ID: 29615460
    [No Abstract]   [Full Text] [Related]  

  • 10. Thioredoxin reductase-1 levels are associated with NRF2 pathway activation and tumor recurrence in non-small cell lung cancer.
    Delgobo M; Gonçalves RM; Delazeri MA; Falchetti M; Zandoná A; Nascimento das Neves R; Almeida K; Fagundes AC; Gelain DP; Fracasso JI; Macêdo GB; Priori L; Bassani N; Bishop AJR; Forcelini CM; Moreira JCF; Zanotto-Filho A
    Free Radic Biol Med; 2021 Dec; 177():58-71. PubMed ID: 34673143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. E3 ligase TRIM15 facilitates non-small cell lung cancer progression through mediating Keap1-Nrf2 signaling pathway.
    Liang M; Wang L; Sun Z; Chen X; Wang H; Qin L; Zhao W; Geng B
    Cell Commun Signal; 2022 May; 20(1):62. PubMed ID: 35534896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene-expression signature regulated by the KEAP1-NRF2-CUL3 axis is associated with a poor prognosis in head and neck squamous cell cancer.
    Namani A; Matiur Rahaman M; Chen M; Tang X
    BMC Cancer; 2018 Jan; 18(1):46. PubMed ID: 29306329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modification of platinum sensitivity by KEAP1/NRF2 signals in non-small cell lung cancer.
    Tian Y; Wu K; Liu Q; Han N; Zhang L; Chu Q; Chen Y
    J Hematol Oncol; 2016 Sep; 9(1):83. PubMed ID: 27601007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Putative chemopreventive molecules can increase Nrf2-regulated cell defense in some human cancer cell lines, resulting in resistance to common cytotoxic therapies.
    Hu L; Miao W; Loignon M; Kandouz M; Batist G
    Cancer Chemother Pharmacol; 2010 Aug; 66(3):467-74. PubMed ID: 19940992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. USP15 negatively regulates Nrf2 through deubiquitination of Keap1.
    Villeneuve NF; Tian W; Wu T; Sun Z; Lau A; Chapman E; Fang D; Zhang DD
    Mol Cell; 2013 Jul; 51(1):68-79. PubMed ID: 23727018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PAQR4 promotes chemoresistance in non-small cell lung cancer through inhibiting Nrf2 protein degradation.
    Xu P; Jiang L; Yang Y; Wu M; Liu B; Shi Y; Shen Q; Jiang X; He Y; Cheng D; Xiong Q; Yang Z; Duan L; Lin J; Zhao S; Shi P; Yang C; Chen Y
    Theranostics; 2020; 10(8):3767-3778. PubMed ID: 32206121
    [No Abstract]   [Full Text] [Related]  

  • 17. Inhibition of TXNRD or SOD1 overcomes NRF2-mediated resistance to β-lapachone.
    Torrente L; Prieto-Farigua N; Falzone A; Elkins CM; Boothman DA; Haura EB; DeNicola GM
    Redox Biol; 2020 Feb; 30():101440. PubMed ID: 32007910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features.
    Solis LM; Behrens C; Dong W; Suraokar M; Ozburn NC; Moran CA; Corvalan AH; Biswal S; Swisher SG; Bekele BN; Minna JD; Stewart DJ; Wistuba II
    Clin Cancer Res; 2010 Jul; 16(14):3743-53. PubMed ID: 20534738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutations in the KEAP1-NFE2L2 Pathway Define a Molecular Subset of Rapidly Progressing Lung Adenocarcinoma.
    Goeman F; De Nicola F; Scalera S; Sperati F; Gallo E; Ciuffreda L; Pallocca M; Pizzuti L; Krasniqi E; Barchiesi G; Vici P; Barba M; Buglioni S; Casini B; Visca P; Pescarmona E; Mazzotta M; De Maria R; Fanciulli M; Ciliberto G; Maugeri-Saccà M
    J Thorac Oncol; 2019 Nov; 14(11):1924-1934. PubMed ID: 31323387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in
    Galan-Cobo A; Sitthideatphaiboon P; Qu X; Poteete A; Pisegna MA; Tong P; Chen PH; Boroughs LK; Rodriguez MLM; Zhang W; Parlati F; Wang J; Gandhi V; Skoulidis F; DeBerardinis RJ; Minna JD; Heymach JV
    Cancer Res; 2019 Jul; 79(13):3251-3267. PubMed ID: 31040157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.